Metlinka 50 Mg/1000 Mg

Metformin Hydrochloride and Sitagliptin, the active ingredients in Metlinka 50 Mg/1000 Mg, are a Biguanide and DPP‑4 inhibitor presented as a 1000 mg/50 mg oral tablet for use in adults with type 2 diabetes mellitus. The combination improves glycaemic control by reducing hepatic glucose output and enhancing insulin secretion in response to meals.

GNH USA supplies Metlinka 50 Mg/1000 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metlinka combines metformin and sitagliptin to address hyperglycaemia in the type 2 diabetes therapeutic pathway. - Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels to achieve target HbA1c. - Metabolic syndrome (as adjunct therapy): assists in attaining glycaemic goals when lifestyle measures are insufficient. - Adults requiring combination therapy: provides enhanced glucose control alongside diet and exercise.

Metlinka may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: loose stools occurring early in therapy. - Abdominal discomfort: cramping or pain. - Headache: transient mild headache. - Metallic taste: altered taste perception. - Decreased appetite: reduced food intake.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or liver injury. - Renal impairment worsening: accumulation of metformin leading to toxicity.

Metlinka requires careful consideration of patient‑specific factors before initiation. - Renal function assessment: avoid or adjust dose in moderate to severe renal impairment. - Hepatic disease monitoring: use with caution in patients with liver dysfunction. - Alcohol consumption: limit intake to reduce risk of lactic acidosis. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Drug‑induced hypoglycaemia: monitor glucose when used with insulin secretagogues. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Metlinka can interact with several medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure when combined with metformin. - Insulin or sulfonylureas: increase risk of severe hypoglycaemia. - Cimetidine: raises sitagliptin plasma concentrations. - Strong CYP3A4 inhibitors: may elevate sitagliptin levels. - Nephrotoxic drugs: exacerbate renal impairment, raising metformin exposure.

Moderate Interactions (Monitor Closely): - Diuretics: can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and potassium. - Warfarin: occasional alterations in INR may occur. - Beta‑blockers: may mask hypoglycaemia symptoms. - Oral corticosteroids: may increase blood glucose, requiring dose adjustments.